Maxigen Biotech Inc
TWSE:1783
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| TW |
|
Maxigen Biotech Inc
TWSE:1783
|
3.9B TWD |
Loading...
|
|
| FR |
|
L'Oreal SA
PAR:OR
|
185.3B EUR |
Loading...
|
|
| UK |
|
Unilever PLC
LSE:ULVR
|
100.5B GBP |
Loading...
|
|
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
4.9T INR |
Loading...
|
|
| UK |
|
HALEON PLC
LSE:HLN
|
33.8B GBP |
Loading...
|
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
31.1B USD |
Loading...
|
|
| DE |
|
Beiersdorf AG
XETRA:BEI
|
16.1B EUR |
Loading...
|
|
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY |
Loading...
|
|
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1T INR |
Loading...
|
|
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD |
Loading...
|
|
| IN |
|
Dabur India Ltd
NSE:DABUR
|
763.5B INR |
Loading...
|
Market Distribution
| Min | -197.7% |
| 30th Percentile | 13.7% |
| Median | 22.1% |
| 70th Percentile | 31.4% |
| Max | 400.8% |
Other Profitability Ratios
Maxigen Biotech Inc
Glance View
Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Maxigen Biotech Inc is 69.2%, which is above its 3-year median of 68.8%.
Over the last 3 years, Maxigen Biotech Inc’s Gross Margin has increased from 57.3% to 69.2%. During this period, it reached a low of 57.3% on Sep 30, 2022 and a high of 71.3% on Mar 31, 2025.
